product pipeline / R&D affecting expense
“The decrease was primarily driven by lower third‑party research and development program expenses, reflecting reduced activity in the ZW220, ZW251, and ZW171 programs.”
ZYME 10-Q
Confirmed
Biotech Cancer Therapies
13 names are moving together; 92% are participating in the current session.
1 observed Confirmed episode
Co-movement
Observed member paths adjusted against SPY. Shading marks the latest observation window.
Members
| TICKER | Company | Sector | Today | Observed activity |
|---|---|---|---|---|
| DNTH | Dianthus Therapeutics, Inc. | Healthcare | -5.2% | Group member |
| PRAX | Praxis Precision Medicines, Inc | Healthcare | -0.2% | Group member |
| SNDX | Syndax Pharmaceuticals, Inc. | Healthcare | -2.3% | 1/2 observed active sessions |
| GILD | Gilead Sciences, Inc. | Healthcare | -0.8% | Group member |
| XENE | Xenon Pharmaceuticals Inc. | Healthcare | -2.4% | 2/2 observed active sessions |
| ABVX | Abivax SA | Healthcare | +0.3% | 1/2 observed active sessions |
| AXSM | Axsome Therapeutics, Inc. | Healthcare | -7.1% | 1/2 observed active sessions |
| IONS | Ionis Pharmaceuticals, Inc. | Healthcare | -2.8% | Group member |
| BHVN | Biohaven Ltd. | Healthcare | — | Group member |
| CMPS | COMPASS Pathways Plc - American | Healthcare | — | Group member |
| PHVS | Pharvaris N.V. | Healthcare | — | Group member |
| TBPH | Theravance Biopharma, Inc. | Healthcare | — | Group member |
| ZYME | Zymeworks Inc. | Healthcare | — | 1/2 observed active sessions |
Why we believe this
Cohort
13 namesParticipation
92% this sessionObserved history
2 daily buildsFiling coverage
11/13 membersdemand / volume affecting revenue
“HIV HIV product sales increased 10% to $5.0 billion for the three months ended March 31, 2026, compared to the same period in 2025, primarily due to higher demand and average realized price, partially offset by unfavorable inventory dynamics.”
GILD 10-Q
product pipeline / R&D
“Impairment on Acquired In-Process Research and Development (IPR&D) Year Ended December 31, 2025 2024 2023 Change 2025 – 2024 (dollars in millions) Impairment on acquired IPR&D $ — $ 17.3 $ — $ (17.3) NM During the year ended December 31, 2024, we recorded an impairment charge of $17.3 million as a result of our decision to discontinue the zanidatamab zovodotin clinical development program which utilized the technology represented by acquired IPR&D assets.”
ZYME 10-K
This identity theme becomes less useful if activity narrows to one or two names instead of remaining broad across the cohort.
Connected, outside the group
ASMB
GILDcustomer · Current intraday read unavailable
Filing receipt · ASMB / GILD
“R&D Services At the commencement of the arrangement and after subsequent amendments, the Company concluded Gilead was a customer and accordingly, the Gilead Collaboratio…”
GILD · customer
RPRX
IONSinvestee · Moving with the group now · 115 min observed
Filing receipt · RPRX / IONS
“These amounts are related to the Royalty Pharma Investments, or Royalty Pharma, transaction, in which we sold a minority interest in our future SPINRAZA and pelacarsen r…”
IONS · investee
JAZZ
ZYMEpartner · Not moving with the group now
Filing receipt · JAZZ / ZYME
“We have entered into separate collaboration and license agreements with BeOne Medicines Ltd.”
ZYME · partner
NBIX
XENEpartner · Not moving with the group now
Filing receipt · NBIX / XENE
“Our Partnered Program with Neurocrine Biosciences In December 2019, we entered into a license and collaboration agreement with Neurocrine Biosciences to develop treatmen…”
XENE · partner
ABBV
SNDXpartner · Not moving with the group now
Filing receipt · ABBV / SNDX
“Included in cost of product sales are royalties owed to AbbVie on Revuforj sales as part of the Vitae License Agreement.”
SNDX · partner
History
2026-07-07 → 2026-07-102 observed active sessions · 11.1% of active names held across the episode